Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
AssigneeGenentech, Inc.
InventorsJames Thomas Koerber, Wyne Pun Lee, Tangsheng Yi, Juan Zhang, Cary Dean Austin, Cecilia Pui Chi Chiu, Joseph Edward Chavarria-Smith, Jawahar Sudhamsu
Life of this patent
Estimating the term…
Abstract
The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
Claims62
An antibody that binds to human KLK7, wherein the antibody comprises a heavy chain variable domain (VH) comprising:
- (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 200, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 201, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12;
- or
- (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 9, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 201, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12;
- or
- (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 200, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 10, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12.
-7. (canceled)
(canceled)
-21. (canceled)
(canceled)
(canceled)
An antibody that binds to human KLK5, wherein the antibody comprises a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 39 or 107, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 40 or 41, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 204, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NOs:
- 43 or 44, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 45, and (f) CDR-L3 comprising an amino acid sequence selected from SEQ ID NO:
- 47.
-36. (canceled)
-49. (canceled)
(canceled)
(canceled)
(canceled)
A bispecific antibody comprising a first binding domain and a second binding domain, wherein the first binding domain binds human KLK7 and the second binding domain binds human KLK5, wherein the first binding domain comprises:
- (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 200, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 201, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12;
- or
- (b) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 9, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 201, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12;
- or
- (c) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 7, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 8, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 200, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 10, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 11, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 12.
(canceled)
(canceled)
(canceled)
-65. (canceled)
-83. (canceled)
A bispecific antibody comprising a first binding domain and a second binding domain, wherein the first binding domain binds human KLK7 and the second binding domain binds human KLK5, wherein the second binding domain comprises a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 39 or 107, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 40 or 41, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 204, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NOs:
- 43 or 44, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 45, and (f) CDR-L3 comprising an amino acid sequence selected from SEQ ID NO:
- 47.
-112. (canceled)
(canceled)
-121. (canceled)
(canceled)
(canceled)
-139. (canceled)
-146. (canceled)
-167. (canceled)
(canceled)
(canceled)
-178. (canceled)
(canceled)
(canceled)
-195. (canceled)
Dependencies are inferred from the claim text.